Predictive, personalized, preventive, participatory (P4) cancer medicine
- PMID: 21364692
- DOI: 10.1038/nrclinonc.2010.227
Predictive, personalized, preventive, participatory (P4) cancer medicine
Abstract
Medicine will move from a reactive to a proactive discipline over the next decade--a discipline that is predictive, personalized, preventive and participatory (P4). P4 medicine will be fueled by systems approaches to disease, emerging technologies and analytical tools. There will be two major challenges to achieving P4 medicine--technical and societal barriers--and the societal barriers will prove the most challenging. How do we bring patients, physicians and members of the health-care community into alignment with the enormous opportunities of P4 medicine? In part, this will be done by the creation of new types of strategic partnerships--between patients, large clinical centers, consortia of clinical centers and patient-advocate groups. For some clinical trials it will necessary to recruit very large numbers of patients--and one powerful approach to this challenge is the crowd-sourced recruitment of patients by bringing large clinical centers together with patient-advocate groups.
Comment in
-
P5 medicine: a plus for a personalized approach to oncology.Nat Rev Clin Oncol. 2011 May 31;8(7):444. doi: 10.1038/nrclinonc.2010.227-c1. Nat Rev Clin Oncol. 2011. PMID: 21629214 No abstract available.
-
P4 medicine or O4 medicine? The perils of population wide, asymptomatic disease screening.Clin Biochem. 2020 Mar;77:62. doi: 10.1016/j.clinbiochem.2020.01.002. Epub 2020 Jan 16. Clin Biochem. 2020. PMID: 31954691 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources